AgeX Therapeutics Q3 2022: Revenue $9K, cash $0.5M, substantial going concern doubt

Serina Therapeutics, Inc.

2023-Q3 EPS reported -$0.20 revenue$26,000

Cash and equivalents $0.5M; company says cash insufficient for next 12 months, raising substantial going concern doubt.
Total revenues $9,000 vs $24,000 prior-year quarter; R&D $0.2M, G&A $1.4M flat.
Borrowed additional $1.0M under $13.16M Secured Note from Juvenescence; $1.5M remaining, draws at Juvenescence's discretion.
$8M principal under earlier 2020 Loan Agreement due March 2023; Secured Note matures Feb 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Serina Therapeutics, Inc. reported financial results for the three months ended September 30, 2022.

Period: the three months ended September 30, 2022
Result: reported results

Exact text from the filing

On November 10, 2022, AgeX issued a press release announcing its financial results for the three months ended September 30, 2022.

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

Serina Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-031372

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.